Nevirapine Teva (nevirapine)
- Region
- 🇪🇺 EU
- Active substance
- nevirapine
- Company
- Teva B.V.
- Status
- Withdrawn
- Therapeutic area
- HIV Infections
- CHMP opinion
- Thu 24 Sep 2009
- EU approval
- Mon 30 Nov 2009
- Designations
- Generic
- Application
- EMEA/H/C/001119
- ATC
- J05AG01
- Official record
- www.ema.europa.eu
Indication
Nevirapine Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV 1 infected adults, adolescents, and children of any age. Most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Viramune Authorised · Boehringer Ingelheim International GmbH
Follow Nevirapine Teva
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.